NEW YORK, May 07, 2018 -- Safirstein Metcalf LLP and HGT Law remind investors that a shareholder “opt-out” lawsuit (“Lawsuit”) has been filed on behalf of a group of retail investors (“Investors”) against Valeant Pharmaceuticals International, Inc. (“Valeant”) and its senior officers for violations of federal securities laws and invite investors to contact the firms.
Previously, on June 24, 2016, a class action complaint was filed in the U.S. District Court for the District of New Jersey, on behalf of a class consisting of all purchasers of the common stock of Valeant (“Class Action”). More than twenty lawsuits have been filed on behalf of institutional investors who have decided to opt out of the Class Action to directly pursue their own claims. To date, the Lawsuit commenced by Safirstein Metcalf LLP and HGT Law is the only opt-out lawsuit that has been filed on behalf of retail investors.
A copy of the complaint filed by Safirstein Metcalf LLP and HGT Law on behalf of the Investors can be found here. For more information on opt-out lawsuits, see our publication here.
If you purchased Valeant common stock during the period from January 4, 2013 through March 15, 2016 and suffered losses of more than $200,000, then you may wish to consider opting out of the existing class action and joining the Lawsuit. A number of large institutional investors such as T. Rowe Price, Blackrock and Prudential Insurance Company have already opted out of the class action. If you would like to learn about the options available to you, please call 1-800-221-0015, email [email protected] or visit www.valeantshareholderlitigation.com
Company: Valeant Pharmaceuticals International, Inc.
Exchange: NYSE
Ticker: VRX
Class Period: 01/04/2013 – 03/15/2016
About Safirstein Metcalf LLP and HGT Law
Safirstein Metcalf LLP focuses its practice on shareholder rights. The law firm also practices in the areas of antitrust and consumer protection. All of the Firm’s legal endeavors are rooted in its core mission: provide investor and consumer protection.
HGT Law is a boutique commercial litigation firm based in New York. The firm focuses on representing investors in securities litigation and corporate governance/derivative litigation.
Attorney advertising. Prior results do not guarantee a similar outcome.
Safirstein Metcalf LLP
Peter Safirstein, Esq.
Safirstein Metcalf LLP
The Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118


AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia
Barclays Downgrades Siemens Energy as Valuation Seen Near Peak
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share
Lockheed Martin, Rheinmetall Plan First ATACMS Missile Production in Germany
SpaceX Stock Draws Bullish Wall Street Coverage Ahead of Nasdaq-100 Inclusion
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal
Shell Raises Q2 Upstream Outlook, Flags Qatar Gas Hit as Shares Rise
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge
Meta Says States Seek $1.4 Trillion in Penalties Over Teen Social Media Addiction Lawsuit
Zhipu AI Stock Jumps on Report of Custom AI Chip Development Plans
TetherMax Rebranding Highlights Official Exchange Partnerships and Transparent Operations 



